Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431 n=55 total, Eyeballing graph n=4 lung -> 3/
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults & Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431 n=55 pts, ORR 75%, 1yr 71% of responses were
NTRK inhibitor for fusion-driven solid tumors - #PrecisionMedicine at work! https://t.co/8gBtWCLoET
RT @mtmdphd: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [2/22/18] @alexdrilon et al. @NEJM https://t.c…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [2/22/18] @alexdrilon et al. @NEJM https://t.co/50fCqsBIL6 #NTRK $LOXO #PrecisionMedicine #NCT02122913 #NCT02637687 #NCT02576431
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/lcS7ajZpxv An important paper to read #PediPath #Pathology
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
#larotrectinib shows good activity in 17 types of TRK fusion–positive cancer in early trial https://t.co/TEQpaGZuoW
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [NEJM] https://t.co/zmn31lmv14
Loxo 101 study has impressive results, including in childhood cancer patients https://t.co/8cksEHI8oY
RT @DavidHongMD: Honored to have been a part of this landmark study! https://t.co/xttbXUaoCy
Larotrectinib produced response in 75% of #cancer patients, regardless of age, tissue of origin, or TRK fusion partner, with mild toxic effects. Full trial results: https://t.co/GMsEvcb3Xd https://t.co/kfoCRtd7Ig @msbracho @SorayaGinecolog @s_v_mastologia
RT @RielyMD: A great team put together this impressive report on targeting TRK fusion cancers (@alexdrilon @DrSarcoma @dhymanNYC among othe…
RT @alexshoushtari: Congrats to @sloan_kettering colleagues @alexdrilon and David Hyman for leading development of fantastic option for pat…
A rare alteration in #cholangiocarcinoma but a viable option! I believe phase 3 study ongoing in all solid tumors https://t.co/YsvshW0AKQ
RT @MLadanyi: Thank you @Aiims1742 ! We are fortunate to have helped identify many of the pts for this remarkable trial via pan-cancer #MSK…
RT @nosequedecir22: Nuevo reto para las agencias, clínicos,evaluadores....ilusión y precaucion https://t.co/jA09ZGJYNf
Nuevo reto para las agencias, clínicos,evaluadores....ilusión y precaucion https://t.co/jA09ZGJYNf
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/ujeNFvDMbP
RT @ContinuumAEP: #NEJMPediatrics Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/sVxmNDjSSs
#NEJMPediatrics Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children https://t.co/sVxmNDjSSs
#scmsm - Larotrectinib in TRK fusion positive cancers including soft-tissue sarcoma https://t.co/qIXdf5Ysnb
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @VinayPrasad82: The promise of tissue agnostic approvals is SCALABILITY. Read this thread and think about that. Read the slide Closely.…
RT @CM_Hake: Den här studien fastnade från senaste Asco-kongressen: https://t.co/qfVAQzLNYS Nu publiceras den i @NEJM: https://t.co/PEe6Xf…
Den här studien fastnade från senaste Asco-kongressen: https://t.co/qfVAQzLNYS Nu publiceras den i @NEJM: https://t.co/PEe6XfAac1 ... med editorial: https://t.co/deOjCr3KZ8
RT @Tony_Calles: Finally published. Congratulations to everyone involved in this study. What a nice piece of work accompanied with a great…
RT @Tony_Calles: Finally published. Congratulations to everyone involved in this study. What a nice piece of work accompanied with a great…
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
Congratulations to @alexdrilon and colleagues for this great achievement. Targeted therapy is still the best option in presence of an oncogenic driver. Impressive response rate regarless of tumor type, fusion partner, and, also here, age of the patients. h
RT @roelverhaak: Oncogene fusions: optimal therapeutic targets! Many more to be discovered at https://t.co/9dGJ695Nkx https://t.co/a5BvMp3F…
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @Dr_R_Kurzrock: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/OUnrVEqR4X
RT @Tony_Calles: Finally published. Congratulations to everyone involved in this study. What a nice piece of work accompanied with a great…
Finally published. Congratulations to everyone involved in this study. What a nice piece of work accompanied with a great editorial by @FAndreMD @alexdrilon @MLadanyi @DrSarcoma @rdoebele @weldeiry @NEJM https://t.co/dsIGywmFZC
RT @GautschiOliver: Tissue agnostic therapy at its very best! IHC screening is easy and compassionate access is possible @loxooncology $LOX…
Congrats to all the authors. Important advance in oncology. @DavidHongMD @rdoebele https://t.co/LONYkpJIEc
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
RT @DrHBurstein: Great story and editorial on TRK targeting @FAndreMD gives superb commentary https://t.co/0ETdcGW8yQ
RT @teamoncology: An impressive list of cancers with TRK fusion responding to a TRK inhibitor. Co-leader of the study is @DavidHongMD from…
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
RT @RielyMD: A great team put together this impressive report on targeting TRK fusion cancers (@alexdrilon @DrSarcoma @dhymanNYC among othe…
RT @alexdrilon: Excited our paper is out!! Congratulations to everyone involved with this, most especially our patients! TRK fusions are hi…
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
RT @n8pennell: Congrats @alexdrilon and colleagues, exciting new target/drug combo for lung cancer and other malignancies as well: Efficacy…
RT @VanAllenLab: Awesome use of cancer genomics to find rare events, treat with the right/effective therapy, and rapidly determine resistan…
Todavía impactado, por favor leedlo https://t.co/pIALLcQ9AB
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/vCLkRtXDGF
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM https://t.co/OUnrVEqR4X
Groundbreaking. Maybe it’s time to reclassify these rare tumors into a single diagnostic group. https://t.co/6qr5jjY2ZB
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…
RT @AndyBiotech: $LOXO Larotrectinib data in TRK Fusion–Positive Cancers in NEJM https://t.co/ZZV4gQH9lD NEJM editorial on the future of…
Thank you @MDAndersonNews for your Support, Excellent Care,, and Prayers. You truly make a difference. Plz read my miracle in my book Living With the Silent Enemy coming soon. Plz support M. D. Anderson to End Cancer. It Takes Lives to Save Lives. https:/
RT @RielyMD: A great team put together this impressive report on targeting TRK fusion cancers (@alexdrilon @DrSarcoma @dhymanNYC among othe…
RT @RielyMD: A great team put together this impressive report on targeting TRK fusion cancers (@alexdrilon @DrSarcoma @dhymanNYC among othe…
RT @MLadanyi: Thank you @Aiims1742 ! We are fortunate to have helped identify many of the pts for this remarkable trial via pan-cancer #MSK…
RT @Aiims1742: You have seen this data few times in the past months - finally out in @NEJM Efficacy of Larotrectinib in TRK Fusion–Positiv…